PDCD1 and neoplasm: Immune checkpoint inhibitors, such as programmed cell death-1(PD-1) mAb, have been used to relieve the restrictions of CTLs28, but the application of PD-1 mAb alone cannot maximize the tumour killing effects of CTLs29.